Quick Answer
Inhibrx Biosciences, Inc. reported Cash And Cash Equivalents At Carrying Value of $124.22 million for the year ending 2025.
- Inhibrx Biosciences, Inc. showed a decrease of -18.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Inhibrx Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2024: $226.86 million | Q3 2024: $196.33 million | Q1 2025: $216.52 million | Q2 2025: $186.57 million | Q3 2025: $153.09 million.
- Over the full 3 years of available data (2023 to 2025), Inhibrx Biosciences, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 55.3%.
- Historical annual values: Fiscal year 2025: $124.22 million | Fiscal year 2024: $152.60 million | Fiscal year 2023: $277.92 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: